Back to Browse Journals » Integrated Blood Pressure Control » Volume 4

Long-term use and tolerability of irbesartan for control of hypertension

Authors Forni V, Wuerzner G, Pruijm M, Burnier M

Published 18 April 2011 Volume 2011:4 Pages 17—26

DOI https://doi.org/10.2147/IBPC.S12211

Review by Single-blind

Peer reviewer comments 4

Valentina Forni, Grégoire Wuerzner, Menno Pruijm, Michel Burnier
Service of Nephrology and Hypertension, Department of Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Abstract: In this review, we discuss the pharmacological and clinical properties of irbesartan, a noncompetitive angiotensin II receptor type 1 antagonist, successfully used for more than a decade in the treatment of essential hypertension. Irbesartan exerts its antihypertensive effect through an inhibitory effect on the pressure response to angiotensin II. Irbesartan 150–300 mg once daily confers a lasting effect over 24 hours, and its antihypertensive efficacy is further enhanced by the coadministration of hydrochlorothiazide. Additionally and partially beyond its blood pressure-lowering effect, irbesartan reduces left ventricular hypertrophy, favors right atrial remodeling in atrial fibrillation, and increases the likelihood of maintenance of sinus rhythm after cardioversion in atrial fibrillation. In addition, the renoprotective effects of irbesartan are well documented in the early and later stages of renal disease in type 2 diabetics. Furthermore, both the therapeutic effectiveness and the placebo-like side effect profile contribute to a high adherence rate to the drug. Currently, irbesartan in monotherapy or combination therapy with hydrochlorothiazide represent a rationale pharmacologic approach for arterial hypertension and early-stage and late-stage diabetic nephropathy in hypertensive type II diabetics.

Keywords: AT1 receptor blockers, renin-angiotensin-aldosterone system, heart, renal, arterial, hypertension

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acute intermittent porphyria caused by novel mutation in HMBS gene, misdiagnosed as cholecystitis

Alfadhel M, Saleh N, Alenazi H, Baffoe-Bonnie H

Neuropsychiatric Disease and Treatment 2014, 10:2135-2137

Published Date: 12 November 2014

Age-associated decrease in global DNA methylation in patients with major depression

Tseng PT, Lin PY, Lee Y, Hung CF, Lung FW, Chen CS, Chong MY

Neuropsychiatric Disease and Treatment 2014, 10:2105-2114

Published Date: 10 November 2014

Vitamin B12, folate, and homocysteine levels in patients with obsessive–compulsive disorder

Türksoy N, Bilici R, Yalçıner A, Özdemir YÖ, Örnek I, Tufan AE, Kara A

Neuropsychiatric Disease and Treatment 2014, 10:1671-1675

Published Date: 9 September 2014

Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure

Spanemberg L, Caldieraro MA, Vares EA, Wollenhaupt-Aguiar B, Kauer-Sant’Anna M, Kawamoto SY, Galvão E, Parker G, Fleck MP

Neuropsychiatric Disease and Treatment 2014, 10:1523-1531

Published Date: 19 August 2014

Sensory disturbances, inhibitory deficits, and the P50 wave in schizophrenia

Vlcek P, Bob P, Raboch J

Neuropsychiatric Disease and Treatment 2014, 10:1309-1315

Published Date: 14 July 2014

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?

Montgomery W, Treuer T, Ye W, Xue HB, Wu SH, Liu L, Kadziola Z, Stensland MD, Ascher-Svanum H

Neuropsychiatric Disease and Treatment 2014, 10:1287-1296

Published Date: 10 July 2014

Corrigendum

Chen ZQ, Liu Y, Zhao JH, Wang L, Feng NP

International Journal of Nanomedicine 2012, 7:1709-1710

Published Date: 30 March 2012

Update on transfusion solutions during surgery: review of hydroxyethyl starches 130/0.4

Ornella Piazza, Giuliana Scarpati, Rosalba Tufano

International Journal of General Medicine 2010, 3:287-295

Published Date: 28 September 2010